Primary Record
Sulprostone
- In stock
- 2,000 g
- Purity
- 98.2 %
- CAS
- 60325-46-4
Compound Identifiers & Properties
- CAS
- 60325-46-4
- PubChem CID
- 5312153
- SMILES
- CS(=O)(=O)NC(=O)CCC/C=C\C[C@@H]1[C@H]([C@@H](CC1=O)O)/C=C/[C@H](COC2=CC=CC=C2)O
- Canonical SMILES
- CS(=O)(=O)NC(=O)CCC/C=C\C[C@H]1C(=O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COc1ccccc1
Names & Synonyms
- Sulprostone
- Nalador
- Sulprostonum
- Sulprostona
- sulproston
- Nalador (TN)
- Sulprostone [USAN:INN]
- Sulprostonum [INN-Latin]
- Sulprostona [INN-Spanish]
- 34.089 Pfizer
- 60325-46-4
- SULPROSTONE [MI]
- RefChem:890029
- 501Q5EQ1GM
- C23H31NO7S
- SULPROSTONE [INN]
- UNII-501Q5EQ1GM
- Sulprostone (USAN/INN)
- SULPROSTONE [USAN]
- D0X2UE
- AC1NSM49
- SHB 286
- CP-34089
- Sch-286
- ZK-57671
- SULPROSTONE [MART.]
- SCHEMBL94842
- SULPROSTONE [WHO-DD]
- EINECS 262-173-0
- CP-34,089
- GTPL1919
- orb1704028
- ZK 57 671
- CHEMBL1472830
- DTXCID0028955
- DTXSID5049029
- G02AD05
- SHB-286
- CHEBI:135755
- UQZVCDCIMBLVNR-TWYODKAFSA-N
- CP 34089
- HMS3648J09
- ZK 57671
- Sulprostone in 5mg/ml Methyl Acetate
- SH-B-286
- ZINC4474665
- C23-H31-N-O7-S
- ZK-57+G1872671
- 2056AH
- Sulprostone, >=95% (HPLC), oil
- AKOS024457401
- CID5312153
- DB12708
- 16-phenoxytetranor-PGE2 methylsulfonylamide
- NCGC00165899-01
- AN-39499
- HY-19360
- J18.517E
- LS-74543
- MS-33188
- B7255
- CS-0015437
- NS00010107
- D02725
- 325S464
- Q410556
- SR-01000946436
- 16-Phenoxy-omega-17,18,19,20-tetranor pge-2 methylsulfonylamide
- SR-01000946436-1
- BRD-K14551499-001-01-7
- (Z)-7-((1R,2R,3R)-3-Hydroxy-2-((E)-(3R)-(3-hydroxy-4-phenoxy-1-butenyl))-5-oxocyclopentyl)-N-(methylsulfonyl)-5-heptenamide
- 16-Phenoxy-17,18,19,20 tetranor prostaglandin E(sub 2) methyl sulfonylamide
- 16-Phenoxy-omega-17,18,19,20-tetranor prostaglandin E2 methylsulfonylamide
- 16-phenoxy-omega-17,18,19,20-tetranor-PGE2 methylsulfonylamide
- 5-Heptenamide, 7-(3-hydroxy-2-(3-hydroxy-4-phenoxy-1-butenyl)-5-oxocyclopentyl)-N-(methylsulfonyl)-, (1R-(1a(Z),2b(1E,3R*),3a))-
- (Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3R)-3-hydroxy-4-phenoxybut-1-enyl]-5-oxocyclopentyl]-N-methylsulfonylhept-5-enamide
- (5Z)-7-[(1R,2R,3R)-3-Hydroxy-2-[(1E,3R)-3-hydroxy-4-buten-1-yl]-5-oxocyclopentyl]-N-(methylsulfonyl)-5-heptenamide
- 5-Heptenamide, 7-(3-hydroxy-2-(3-hydroxy-4-phenoxy-1-butenyl)-5-oxocyclopentyl)-N-(methylsulfonyl)-, (1R-(1alpha(Z),2beta(1E,3R*),3alpha))-
- (5Z)-7-((1R,2R,3R)-3-hydroxy-2-((1E,3R)-3-hydroxy-4-phenoxybut-1-en-1-yl)-5-oxocyclopentyl)-N-methanesulfonylhept-5-enamide
- (5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3R)-3-hydroxy-4-phenoxybut-1-en-1-yl]-5-oxocyclopentyl]-N-methanesulfonylhept-5-enamide
- (Z)-7-((1R,2R,3R)-3-hydroxy-2-((E,3R)-3-hydroxy-4-(phenoxy)but-1-enyl)-5-oxocyclopentyl)-N-methylsulfonylhept-5-enamide
- (Z)-7-[(1R,2R,3R)-3-Hydroxy-2-[(1E,3R)-3-hydroxy-4-phenoxy-1-butenyl]-5-oxocyclopentyl]-N-(methylsulfonyl)-5-heptenamide
- (Z)-7-[(1R,2R,3R)-3-Hydroxy-2-[(E)-(3R)-(3-hydroxy-4-phenoxy-1-butenyl)]-5-oxocyclopentyl]-N-(methylsulfonyl)-5-heptenamide
- (Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3R)-3-hydroxy-4-(phenoxy)but-1-enyl]-5-oxocyclopentyl]-N-methylsulfonylhept-5-enamide
- (Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3R)-3-hydroxy-4-phenoxy-but-1-enyl]-5-oxo-cyclopentyl]-N-methylsulfonyl-hept-5-enamide
- (Z)-N-Methylsulfonyl-7-[(1R)-2beta-[(E,R)-4-phenoxy-3-hydroxy-1-butenyl]-3alpha-hydroxy-5-oxocyclopentan-1alpha-yl]-5-heptenamide
- (Z)-N-Methylsulfonyl-7-[(1R)-2beta-[(E,R)-4-phenoxy-3-hydroxy-1-butenyl]-3alpha-hydroxy-5-oxocyclopentane-1alpha-yl]-5-hepteneamide
- 262-173-0
- 5-Heptenamide, 7-(3-hydroxy-2-(3-hydroxy-4-phenoxy-1-butenyl)-5-oxocyclopentyl)-N-(methylsulfonyl)-, (1R-(1-alpha(Z),2-beta(1E,3R*),3-alpha))-
- 5-Heptenamide, 7-[3-hydroxy-2-(3-hydroxy-4-phenoxy-1-butenyl)-5-oxocyclopentyl]-N-(methylsulfonyl)-, [1R-[1.alpha.(Z),2.beta.(1E,3R*),3.alpha.]]-
- 5Z,13E-18R,11R,12R,15R- dihydroxy-9-oxo-16-phenoxy-17,18,19,20-tetranor- 5,13-prostadienoic acid methylsulfonylamide
- 5Z,13E-18R,11R,12R,15R-dihydroxy-9-oxo-16-phenoxy-17,18,19,20-tetranor-5,13-prostadienoic acid methylsulfonylamide